Literature DB >> 23812597

An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.

R Niimi1, T Kono, A Nishihara, M Hasegawa, A Matsumine, T Nakamura, T Kono, A Sudo.   

Abstract

UNLABELLED: About two thirds of patients with a procollagen type I N-terminal propeptide (PINP) increase of >80 μg/l at 1 month after starting teriparatide therapy showed a ≥10 % increase in lumbar spine (LS) bone mineral density (BMD) from baseline at 12 months. We recommend this algorithm as an aid in the clinical management of patients treated with daily teriparatide.
INTRODUCTION: An algorithm using PINP is provided in osteoporotic patients with teriparatide treatment. The correlations between the early changes in PINP and the subsequent BMD changes after daily teriparatide therapy were studied to develop an algorithm to monitor patients.
METHODS: We evaluated whether early changes in PINP correlated with the changes in BMD at 12 months and developed an algorithm using the early changes in PINP to predict the upcoming BMD increases.
RESULTS: The highest correlation coefficient for the relationship between PINP and LS BMD response was determined for the absolute change in PINP at 1 month and the percent change in LS BMD at 12 months (r = 0.36, p <0.01). Using a receiver operator curve analysis, we determined that an 80 μg/l increase in PINP was the most convenient predictor of a 10% increase in LS BMD from baseline (area under curve = 0.72). Using a cut-off value of 80 μg/l, the positive predictive value for predicting a 10% increase in LS BMD from baseline to 12 months was 65%.
CONCLUSION: Greater short-term changes in PINP with teriparatide therapy are associated with greater 12-month increases in LS BMD. About two thirds of patients with a PINP increase of >80 μg/l at 1 month after starting treatment showed a ≥10 % increase in LS BMD from baseline at 12 months. We recommend this algorithm as an aid in the clinical management of patients treated with teriparatide.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812597     DOI: 10.1007/s00198-013-2426-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  14 in total

1.  Diagnostic criteria for primary osteoporosis: year 2000 revision.

Authors:  H Orimo; Y Hayashi; M Fukunaga; T Sone; S Fujiwara; M Shiraki; K Kushida; S Miyamoto; S Soen; J Nishimura; Y Oh-Hashi; T Hosoi; I Gorai; H Tanaka; T Igai; H Kishimoto
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

2.  PINP as an aid for monitoring patients treated with teriparatide.

Authors:  Mika Tsujimoto; Peiqi Chen; Akimitsu Miyauchi; Hideaki Sowa; John H Krege
Journal:  Bone       Date:  2010-12-17       Impact factor: 4.398

3.  Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.

Authors:  Peiqi Chen; Julie H Satterwhite; Angelo A Licata; E Michael Lewiecki; Adrien A Sipos; Derek M Misurski; Rachel B Wagman
Journal:  J Bone Miner Res       Date:  2005-01-18       Impact factor: 6.741

4.  Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.

Authors:  D M Black; J P Bilezikian; S L Greenspan; C Wüster; M Muñoz-Torres; H G Bone; C J Rosen; H S Andersen; D A Hanley
Journal:  Osteoporos Int       Date:  2012-08-29       Impact factor: 4.507

5.  Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.

Authors:  Akimitsu Miyauchi; Toshio Matsumoto; Toshitsugu Sugimoto; Mika Tsujimoto; Margaret R Warner; Toshitaka Nakamura
Journal:  Bone       Date:  2010-05-24       Impact factor: 4.398

6.  Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Authors:  S L Greenspan; R A Parker; L Ferguson; H N Rosen; L Maitland-Ramsey; D B Karpf
Journal:  J Bone Miner Res       Date:  1998-09       Impact factor: 6.741

7.  Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.

Authors:  Harald Dobnig; Adrien Sipos; Yebin Jiang; Astrid Fahrleitner-Pammer; Louis-Georges Ste-Marie; J Christopher Gallagher; Imre Pavo; Jingyuan Wang; Erik F Eriksen
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

8.  Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.

Authors:  P Ravn; B Clemmesen; C Christiansen
Journal:  Bone       Date:  1999-03       Impact factor: 4.398

9.  Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.

Authors:  Peiqi Chen; Paul D Miller; Pierre D Delmas; Derek A Misurski; John H Krege
Journal:  J Bone Miner Res       Date:  2006-11       Impact factor: 6.741

10.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

Authors:  Jackie A Clowes; Nicola F A Peel; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

View more
  11 in total

1.  A retrospective analysis of nonresponse to daily teriparatide treatment.

Authors:  R Niimi; T Kono; A Nishihara; M Hasegawa; T Kono; A Sudo
Journal:  Osteoporos Int       Date:  2016-04-07       Impact factor: 4.507

2.  Analysis of daily teriparatide treatment for osteoporosis in men.

Authors:  R Niimi; T Kono; A Nishihara; M Hasegawa; A Matsumine; T Kono; A Sudo
Journal:  Osteoporos Int       Date:  2015-01-08       Impact factor: 4.507

3.  Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.

Authors:  R Niimi; T Kono; A Nishihara; M Hasegawa; A Matsumine; T Kono; A Sudo
Journal:  Osteoporos Int       Date:  2016-01-13       Impact factor: 4.507

4.  Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients.

Authors:  Rui Niimi; Toshibumi Kono; Atsushi Nishihara; Masahiro Hasegawa; Toshihiko Kono; Akihiro Sudo
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

5.  Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women.

Authors:  Mary P Kotlarczyk; Subashan Perera; Neil M Resnick; David A Nace; Susan L Greenspan
Journal:  Arch Osteoporos       Date:  2020-05-26       Impact factor: 2.617

Review 6.  A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.

Authors:  J F Chen; K H Yang; Z L Zhang; H C Chang; Y Chen; H Sowa; S Gürbüz
Journal:  Osteoporos Int       Date:  2014-08-20       Impact factor: 4.507

7.  Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial.

Authors:  Rui Niimi; Toshibumi Kono; Atsushi Nishihara; Masahiro Hasegawa; Toshihiko Kono; Akihiro Sudo
Journal:  JBMR Plus       Date:  2018-06-02

8.  Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation.

Authors:  Takanori Yamamoto; Mika Tsujimoto; Hideaki Sowa
Journal:  Clin Interv Aging       Date:  2015-07-06       Impact factor: 4.458

Review 9.  PINP as a biological response marker during teriparatide treatment for osteoporosis.

Authors:  J H Krege; N E Lane; J M Harris; P D Miller
Journal:  Osteoporos Int       Date:  2014-03-06       Impact factor: 4.507

10.  Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.

Authors:  Atsushi Nishikawa; Takehiro Ishida; Masanori Taketsuna; Fumito Yoshiki; Hiroyuki Enomoto
Journal:  Clin Interv Aging       Date:  2016-07-06       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.